Endotronix publishes 6-month PROACTIVE-HF results in JACC-HF

Today Endotronix announced the publication of the 6-month results from the PROACTIVE-HF clinical trial in the August issue of the Journal of the American College of Cardiology: Heart Failure (JACC-HF).

To read the complete PROACTIVE-HF trial results, click here.

The trial demonstrated the safety and efficacy of the Cordella Pulmonary Artery (PA) Sensor System for remote heart failure treatment in New York Heart Association (NYHA) class III patients.

In the U.S., the Cordella™ PA Sensor System is Rx Only. CAUTION: Federal law restricts this device to sale by or on the order of a physician.
In Europe, the Cordella™ PA Sensor System is Exclusively for Clinical Investigation.
The Cordella™ HF System is commercially available in the U.S. and Europe